POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com Will receive actinium-225 in 2022 from the US Department of Energy Isotope Program to support early-stage pipeline Dosimetry data from the lead-in cohort of the SPLASH trial in mCRPC will be published February 25th in…

Read More
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm

Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm

Fujifilm to Acquire Atara’s Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million Parties to Enter Long-Term Supply Agreement for Clinical and Commercial Product Manufacturing Transaction Expected to Result in Reduced Operating Expenses for Atara Upon Closing, Atara’s Cash Expected to Fund Planned Operations into Q4 2023 Company to Host Live…

Read More